166 related articles for article (PubMed ID: 37495516)
1. Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating MEK1/2-ERK1/2 signaling in canine melanoma cells.
Yamamoto M; Fujiwara N
J Vet Med Sci; 2023 Sep; 85(9):977-984. PubMed ID: 37495516
[TBL] [Abstract][Full Text] [Related]
2. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
Cronise KE; Hernandez BG; Gustafson DL; Duval DL
Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
[TBL] [Abstract][Full Text] [Related]
3. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
4. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W
Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293
[TBL] [Abstract][Full Text] [Related]
5. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes.
Adams DG; Coffee RL; Zhang H; Pelech S; Strack S; Wadzinski BE
J Biol Chem; 2005 Dec; 280(52):42644-54. PubMed ID: 16239230
[TBL] [Abstract][Full Text] [Related]
6. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
7. Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons.
Mao L; Yang L; Arora A; Choe ES; Zhang G; Liu Z; Fibuch EE; Wang JQ
J Biol Chem; 2005 Apr; 280(13):12602-10. PubMed ID: 15661743
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
Vaidhyanathan S; Mittapalli RK; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2014 Aug; 42(8):1292-300. PubMed ID: 24875464
[TBL] [Abstract][Full Text] [Related]
10. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
[TBL] [Abstract][Full Text] [Related]
11. Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells.
Schramek H; Feifel E; Healy E; Pollack V
J Biol Chem; 1997 Apr; 272(17):11426-33. PubMed ID: 9111053
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
14. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
[TBL] [Abstract][Full Text] [Related]
15. p38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis.
Grethe S; Pörn-Ares MI
Cell Signal; 2006 Apr; 18(4):531-40. PubMed ID: 15972258
[TBL] [Abstract][Full Text] [Related]
16. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
Tong Z; Singh G; Rainbow AJ
Cancer Res; 2002 Oct; 62(19):5528-35. PubMed ID: 12359764
[TBL] [Abstract][Full Text] [Related]
17. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
[TBL] [Abstract][Full Text] [Related]
18. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
Wu PK; Hong SK; Park JI
Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
[TBL] [Abstract][Full Text] [Related]
19. Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics.
Urasaki Y; Fiscus RR; Le TT
Sci Rep; 2018 Jul; 8(1):9991. PubMed ID: 29968772
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway.
Mhaidat NM; Zhang XD; Jiang CC; Hersey P
Clin Cancer Res; 2007 Feb; 13(4):1308-14. PubMed ID: 17317842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]